Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.

被引：13

作者：

Koshkin, Vadim S.

Sonpavde, Guru P.

Hwang, Clara

Mellado, Begona

Tomlinson, Gareth

Shimura, Masashi

Chisamore, Michael Jon

Gil, Maciej

Loriot, Yohann

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[3] Henry Ford Hlth Syst, Detroit, MI USA

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Taiho Pharma Canada Inc, Oakville, ON, Canada

[6] Taiho Oncol Inc, Princeton, NJ USA

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Univ Paris Saclay, Gustave Roussy, INSERMU981, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

501

引用

页数：3